Why the study?
Prior findings linking carbonic anhydrases to both glaucoma pathogenesis and aortic atherosclerosis suggested a relationship between the two conditions and a potential therapeutic role for methazolamide.
Is there an association between glaucoma and atherosclerosis, and does methazolamide reduce LDL levels in patients with both conditions?
Is there an association between glaucoma and atherosclerosis, and does methazolamide reduce LDL levels in patients with both conditions?
This study identifies a significant epidemiological association between glaucoma and atherosclerosis, and suggests that the carbonic anhydrase inhibitor methazolamide may have LDL-lowering effects.
No takes yet. Share an insight, caveat, or question.
MTZ may attenuate atherosclerosis in preclinical models; leaves open human cardiovascular translation.
Song et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: